Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Benzylpenicilloyl polylysine | 4-Bromo-2,5-dimethoxyphenethylamine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Hyaluronidase (ovine) | The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Hyaluronidase (human recombinant) | The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Hyaluronidase | The risk or severity of adverse effects can be increased when Hyaluronidase is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Spironolactone | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Spironolactone. |
| Methysergide | Methysergide may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Cabergoline | Cabergoline may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Dihydroergotamine | Dihydroergotamine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Methylergometrine | Methylergometrine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Lisuride | Lisuride may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Ergotamine | Ergotamine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Nicergoline | Nicergoline may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Ergoloid mesylate | Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Pergolide | Pergolide may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Bromocriptine | Bromocriptine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Ergometrine | Ergometrine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Lysergic acid diethylamide | Lysergic acid diethylamide may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Dihydroergocornine | Dihydroergocornine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Dihydroergocristine | Dihydroergocristine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Dihydroergocryptine | Dihydroergocryptine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Terguride | Terguride may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Metergoline | Metergoline may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Venlafaxine | Venlafaxine may increase the tachycardic activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Nefazodone | Nefazodone may increase the tachycardic activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Duloxetine | Duloxetine may increase the tachycardic activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Sibutramine | Sibutramine may increase the tachycardic activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Milnacipran | Milnacipran may increase the tachycardic activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Desvenlafaxine | Desvenlafaxine may increase the tachycardic activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Levomilnacipran | Levomilnacipran may increase the tachycardic activities of 4-Bromo-2,5-dimethoxyphenethylamine. |
| Ziprasidone | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Ziprasidone. |
| Olanzapine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Olanzapine. |
| Alfuzosin | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Alfuzosin. |
| Clozapine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Clozapine. |
| Promazine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Promazine. |
| Prazosin | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Prazosin. |
| Chlorpromazine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Chlorpromazine. |
| Doxazosin | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Doxazosin. |
| Nicardipine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Nicardipine. |
| Verapamil | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Verapamil. |
| Thioridazine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Thioridazine. |
| Phentolamine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Phentolamine. |
| Tamsulosin | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Tamsulosin. |
| Risperidone | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Risperidone. |
| Propiomazine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Propiomazine. |
| Tolazoline | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Tolazoline. |
| Trifluoperazine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Trifluoperazine. |
| Flupentixol | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Flupentixol. |
| Quinidine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Quinidine. |
| Phenoxybenzamine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Phenoxybenzamine. |
| Terazosin | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Terazosin. |
| Quetiapine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Quetiapine. |
| Aripiprazole | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Aripiprazole. |
| Paliperidone | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Paliperidone. |
| Periciazine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Periciazine. |
| Acepromazine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Acepromazine. |
| Thioproperazine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Thioproperazine. |
| Zuclopenthixol | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Zuclopenthixol. |
| Dronedarone | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Dronedarone. |
| Iloperidone | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Iloperidone. |
| Pizotifen | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Pizotifen. |
| Silodosin | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Silodosin. |
| Asenapine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Asenapine. |
| Indoramin | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Indoramin. |
| Brexpiprazole | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Brexpiprazole. |
| Trimazosin | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Trimazosin. |
| Niguldipine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Niguldipine. |
| Bunazosin | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Bunazosin. |
| Propiverine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Propiverine. |
| Urapidil | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Urapidil. |
| Aripiprazole lauroxil | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Aripiprazole lauroxil. |
| Droperidol | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Droperidol. |
| Trazodone | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Trazodone. |
| Methotrimeprazine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Methotrimeprazine. |
| Amitriptyline | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Amitriptyline. |
| Imipramine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Imipramine. |
| Nortriptyline | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Nortriptyline. |
| Amoxapine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Amoxapine. |
| Trimipramine | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Trimipramine. |
| Doxepin | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Doxepin. |
| Protriptyline | The risk or severity of hypertension can be increased when Protriptyline is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Desipramine | The risk or severity of hypertension can be increased when Desipramine is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Clomipramine | The risk or severity of hypertension can be increased when Clomipramine is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Amineptine | The risk or severity of hypertension can be increased when Amineptine is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Dimetacrine | The risk or severity of hypertension can be increased when Dimetacrine is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Butriptyline | The risk or severity of hypertension can be increased when Butriptyline is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Dosulepin | The risk or severity of hypertension can be increased when Dosulepin is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Tianeptine | The risk or severity of hypertension can be increased when Tianeptine is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Oxaprotiline | The risk or severity of hypertension can be increased when Oxaprotiline is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Opipramol | The risk or severity of hypertension can be increased when Opipramol is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Amitriptylinoxide | The risk or severity of hypertension can be increased when Amitriptylinoxide is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Dibenzepin | The risk or severity of hypertension can be increased when Dibenzepin is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Quinupramine | The risk or severity of hypertension can be increased when Quinupramine is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Melitracen | The risk or severity of hypertension can be increased when Melitracen is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Lofepramine | The risk or severity of hypertension can be increased when Lofepramine is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Iprindole | The risk or severity of hypertension can be increased when Iprindole is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Imipramine oxide | The risk or severity of hypertension can be increased when Imipramine oxide is combined with 4-Bromo-2,5-dimethoxyphenethylamine. |
| Esmolol | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Esmolol. |
| Betaxolol | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Betaxolol. |
| Metoprolol | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Metoprolol. |
| Atenolol | The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Atenolol. |